Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma

Authors

  • Aymeric Hennemann Dermatology Department and Inserm Unit 1098, Franche Comté University and University Hospital, Besancon, France
  • Marie Agnès Collonge Rame Genetic Department, University Hospital, Besancon, France
  • Eve Puzenat Dermatology Department and Inserm Unit 1098, Franche Comté University and University Hospital, Besancon, France
  • Cécile Ged Univ. Bordeaux, INSERM, BMGIC, Bordeaux, France
  • Sylvain Harbon Saint Vincent Clinic, Besançon, France
  • François Aubin Dermatology Department and Inserm Unit 1098, Franche Comté University and University Hospital, Besancon, France
  • Charlée Nardin Dermatology Department and Inserm Unit 1098, Franche Comté University and University Hospital, Besancon, France

DOI:

https://doi.org/10.1080/0284186X.2022.2109425

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2022-09-02

How to Cite

Hennemann, A., Agnès Collonge Rame, M., Puzenat, E., Ged, C., Harbon, S., Aubin, F., & Nardin, C. (2022). Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma. Acta Oncologica, 61(9), 1140–1142. https://doi.org/10.1080/0284186X.2022.2109425

Issue

Vol. 61 No. 9 (2022): Acta Oncologica

Section

Articles